With the introduction of potent antiretroviral therapy, the incidence of opportunistic infections (OIs) as well as death has dramatically decreased since 1996. Opportunistic infections are seen mainly in three groups: (1) newly diagnosed patients not receiving antiretroviral therapy and presenting with an OI, (2) patients nonadherent to antiretroviral and OI treatment regimens or (3) patients whose antiretroviral therapy has failed. This article will review the most common opportunistic infections (OIs) seen in the HIV-infected individual and their treatment. The current guidelines for the prophylaxis against these OIs will also be discussed.
Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997; 337:734-739.
2.
Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338:853-860.
3.
Michelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS. 1998; 12:1815-1822.
4.
Phair T, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med. 1990; 322:161-165.
5.
Allegra CJ, Chabner BA, Tuazon CU, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987; 317:978-985.
6.
Sattler FR, Cowan R, Nielsen DM, et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med. 1988; 109:280-287.
7.
Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A prospective randomized trial. Ann Intern Med. 1986; 105:37-44.
8.
Klein NC, Duncanson FP, Lenox TH, et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS. 1992; 6:301-305.
9.
Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis cariniipneumonia in patients with AIDS: A double-blind, randomized trial of oral trimethoprimsulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. Ann Intern Med. 1996; 124:792-802.
10.
Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprimdapsone. N Engl J Med. 1990; 323:776-782.
11.
Toma EM, Thorne A, Singer J, et al. Clindamycin with primaquine vs. trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). Clin Infect Dis. 1998; 27:524-530.
12.
Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993; 328:1521-1527.
13.
Sattler FR, Frame P, Davis R, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS clinical trials group protocol 029/031. J Infect Dis. 1994; 170:165-172.
14.
Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med. 1994; 121:174-180.
15.
Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984; 100:663-671.
16.
Murphey SA, Josephs AS. Acute pancreatitis associated with pentamidine therapy. Arch Intern Med. 1981; 141:56-58.
17.
Zuger A, Wolf BZ, El-Sadr W, et al. Pentamidine-associated fatal acute pancreatitis. JAMA. 1986; 256:2383-2385.
18.
Wharton JM, Demopulos PA, Goldschlager N.Torsade de pointes during administration of pentamidine isethionate. Am J Med. 1987; 83:571-576.
19.
Cortese LM, Gasser RA, Bjornson DC, et al. Prolonged recurrence of pentamidine-induced torsades de pointes. Ann Pharmacother. 1992; 26:1365-1369.
20.
Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome. Am J Med. 1989; 87:260-262.
21.
Foisy MM, Slayter KL, Hewitt FG, et al. Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to pentamidine. Ann Pharmacother. 1994; 28:1025-1028.
22.
Pertel P, Hirschtick R.Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Clin Infect Dis. 1994; 18:630-632.
23.
Holtzer CD, Flaherty JF, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone. Pharmacother. 1998; 18:831-835.
24.
Kovacs JA. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. Lancet. 1992; 340:637-638.
25.
Torres RA, Weinberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Group. Clin Infect Dis. 1997; 24:422-429.
26.
Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis cariniipneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990; 323:1451-1457.
27.
Gagnon S, Boota AM, Fischl MA, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990; 323:1444-1450.
28.
Nielsen TL, Eeftinck-Schattenkerk JK, Jensen BN, et al. Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia. J AIDS. 1992; 2:726-731.
29.
Monaner JSG, Lawson LM, Levitt N, et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1990:113:14-20.
30.
Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med.1990; 323:1500-1504.
31.
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1999; 48:1-66.
32.
Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1995; 332:693-699.
33.
Schneider MME, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of 2 doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. J Infect Dis. 1995; 171:1632-1636.
34.
Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992; 117:106-111.
35.
Podzamczer D, Salazar A, Jimenez J, et al. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med. 1995; 122:755-761.
36.
Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group protocol 021. N Engl J Med. 1992; 327:1842-1848.
37.
El-Sadr W, Luskin-Hawk R, Yurik TM, et al. A randomized trial of daily and thrice weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons: Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis. 1999; 29:775-783.
38.
Para MF, Dohn M, Frame P, et al. ACTG 268 Trial-gradual initiation of trimethoprim/sulfamethoxazole (T/S) as primary prophylaxis for Pneumocystis carinii pneumonia (PCP). In: Programs and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, D.C. Abstract 65.
39.
Leoung G, Standford J, Giordano M, et al. A randomized, double-blind trial of TMP/SMX dose escalation vs. direct challenge in HIV+ persons at risk for PCP and with prior treatment-limiting rash or fever. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-29, 1997; Toronto Canada. Abstract No. LB10.
40.
Saah AJ, Hoover DR, Peng Y, et al. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. JAMA. 1995; 273:1197-1202.
41.
Helweg-Larson J, Benfield TL, Eugen-Olsen J, et al. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet. 1999; 354:1347-1351.
42.
Kazanjian P, Locke AB, Hossler PA. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS. 1998; 12:873-878.
43.
Opravil M, Hirschel B, Lazzarin A, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis. 1995; 20:531-541.
44.
Girard PM, Landman R, Gaudebout C, et al. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med. 1993; 328:1514-1520.
45.
Rizzardi GP, Lazzarin A, Musicco M, et al. Better efficacy of twice monthly than monthly aerosolized pentamidine for secondary prophylaxis of Pneumocystis cariniipneumonia in patients with AIDS. An Italian multicenter randomized controlled trial. JInfect. 1995; 31:99-105.
46.
Golden JA, Katz MH, Chernoff DN, et al. A randomized comparison of once monthly or twice monthly high dose aerosolized pentamidine prophylaxis. Chest. 1993; 104:743-750.
47.
Karboski JA, Godley PJ. Inhaled pentamidine and hypoglycemia. Ann Intern Med. 1988;108:490.
48.
Murphy RL, Noskin GA, Ehrenpreis ED. Acute pancreatitis associated with aerosolized pentamidine. Am J Med. 1990; 88:53N-56N.
49.
Caldwell P, Murphy R, Chan C.Atovaquone suspension for prophylaxis of Pneumocystis carinii pneumonia (PCP): effects of baseline prophylaxis on safety and efficacy. In: Conference Records, 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 22178.
50.
El-Sadr WM, Murphy RL, Yurik T, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med. 1998; 339:1889-1895.
51.
Schneider MME, Borleffs JJC, Stolk RP, et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy. Lancet. 1999; 353:201-203.
52.
Furrer H, Egger M, Opvavil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. N Engl J Med. 1999; 340:1301-1306.
53.
Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis cariniipneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet. 1999; 353:1293-1298.
54.
Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis. 2000; 181:1635-1642.
55.
Koletar SL, Heald AE, Murphy RL, et al. Discontinuing primary and secondary PCP prophylaxis in patients who have increased CD4 counts in response to antiretroviral therapy: preliminary results-ACTG 888. In: Programs and abstracts of the 7th Conference on Retro-viruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 243.
56.
Ledergerber B, Mocroft A, Reiss P, et al. Is it safe to discontinue secondary prophylaxis for PCP in HIV-infected patients treated with HAART: results from eight prospective European cohorts. In: Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30- February 2, 2000; San Francisco, CA. Abstract LB5.
Kovacs JA, Kovacs AA, Polis M, et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med. 1985; 103:533-538.
59.
Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans of the prostate after successful treatment of meningitis. Ann Intern Med. 1989;111:125-128.
60.
Zeind CS, Cleveland KO, Menon M, et al. Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. Pharmacother. 1996; 16:547-561.
61.
Zuger A, Louie E, Holzmann RS, et al. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann Intern Med. 1986; 104:234-240.
62.
Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med. 1992; 326:83-89.
63.
Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med.1989; 321:794-799.
64.
Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med. 1979; 301:126-131.
65.
Dismukes WE, Cloud G, Gallis HA, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 1987; 317:334-341.
66.
Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. Ann Intern Med. 1990; 113:183-187.
67.
de Lalla F, Pellizzer G, Vaglia A, et al. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin Infect Dis. 1995; 20:263-266.
68.
de Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS. 1992; 6:185-190.
69.
Van Der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997; 337:15-21.
70.
Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999; 28:291-296.
71.
Haubrick RH, Haghighat D, Bozzette SA, et al. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. J Infect Dis. 1994; 170:238-242.
72.
Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother. 1992; 36:690-692.
73.
Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994; 19:741-745.
74.
Viviani MA, Tortorano AM, Langer M, et al. Experience with itraconazole in cryptococcosis and aspergillosis. J Infect Dis. 1989; 18:151-165.
75.
Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS. 1993; 7:829-835.
76.
Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997; 17:1463-1471.
77.
Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1996; 22:315-322.
78.
Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992; 326:793-798.
79.
Havlir DV, Dube MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis. 1998; 27:1369-1375.
80.
Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1995; 332:700-705.
Grant IH, Gold JWM, Rosenblum M, et al. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis. AIDS. 1990; 4:519-521.
84.
Arendt G, Von Giesen H-J, Hefter H, et al. Long-term course and outcome in AIDS patients with cerebral toxoplasmosis. Acta Neurol Scand. 1999; 100:178-184.
85.
Dannemann B, McCutchan A, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med. 1992:116:33-43.
86.
Carrazana EJ, Rossitch E, Samuels MA. Cerebral toxoplasmosis in the acquired immune deficiency syndrome. Clin Neurol Neurosurg. 1989; 91:291-299.
87.
Leport C, Raffi F, Matheron S, et al. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Am J Med. 1988; 84:94-100.
88.
Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992; 327:1643-1648.
89.
Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1993; 329:995-1000.
90.
Saba J, Morlat P, Raffi F, et al. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis. 1993; 12:853-856.
91.
Wiselka MJ, Read R, Finch RG. Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. J Infect. 1996; 33:227-229.
92.
Wynn RF, Leen CLS, Brettle RP. Azithromycin for cerebral toxoplasmosis in AIDS. Lancet. 1993; 341:243-244 (letter).
93.
Fernandez-Martin J, Loport C, Morlat P, et al. Pyrimethamine-clarithromycin combination for therapy of acute toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1991; 35:2049-2052.
94.
Morris JT, Kelly JW. Effective treatment of cerebral toxoplasmosis with doxycycline. Am J Med. 1992; 93:107-108 (letter).
95.
Hagberg L, Palmertz B, Lindberg J.Doxycycline and pyrimethamine for toxoplasmic encephalitis. Scand J Infect Dis. 1993; 167:1422-1426.
96.
Dhiver C, Milandre C, Poizot-Martin I, et al. 5-Fluorouracil-clindamycin for treatment of cerebral toxoplasmosis. AIDS. 1993; 7:143-144 (letter).
97.
Canessa A, Del Bono V, De Ieo P, et al. Cotrimoxazole therapy of toxoplasma gondiiencephalitis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1992; 11:125-130.
98.
Masur H, Polis MA, Tuazon CU, et al. Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS. J Infect Dis. 1993; 167:1422-1426.
99.
Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis. 1991; 164:170-177.
100.
Araujo FG, Huskinson J, Remington JS. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrobiol Agents Chemother. 1991; 35:293-299.
101.
Podzamczer D, Miro JM, Bolao F, et al. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1995; 123:175-180.
102.
Podzamczer D, Miro JM, Ferrer E, et al. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2000; 19:89-95.
103.
Heald A, Flepp M, Chave JP, et al. Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med. 1991; 115:760-763.
104.
Katlama C, Mouthon B, Gourdon D, et al. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. AIDS. 1996; 10:1107-1112.
105.
Guex A, Radziwill AJ, Bucher HC. Discontinuation of secondary prophylaxis for toxoplasmic encephalitis with human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy. Clin Infect Dis. 2000; 30:602-603.
106.
Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med. 1996; 335:377-383
107.
Kemper CA, Meng TC, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Ann Intern Med. 1992; 116:466-472.
108.
Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: a controlled clinical trial. Am Rev Respir Dis. 1991; 144:564-569.
109.
Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med. 1994; 121:905-911.
110.
Cohn DL, Fisher EJ, Peng GT, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Clin Infect Dis. 1999; 29:125-133.
111.
Benson CA. Chapter 30: Mycobacterium avium Complex and Other Atypical Mycobacterial Infections. In: Dolin R, Masur H, Saag MS, eds. AIDS Therapy, 1st edition. Philadelphia, PA: Churchill Livingstone, 1999:375-391.
112.
Inderlied CB, Kemper CA, Bermudez LEM. The Mycobacterium avium complex. Clin Microbiol Rev. 1993; 6:266-310.
113.
Ward TT, Rimland D, Kauffman C, et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Clin Infect Dis. 1998; 27:1278-1285.
114.
Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS. 1997; 11:311-317.
115.
Masur H.Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med. 1993; 329:898-904.
116.
Dube MP, Sattler FR, Torriani FS, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J Infect Dis. 1997; 176:1225-1232.
117.
Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS clinical trials group 196/Terry Beirn community programs for clinical research on AIDS 009 protocol team. J Infect Dis. 2000; 181:1289-1297.
118.
Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996; 335:384-391.
119.
Oldfield EC III, Fessel WJ, Dunne MW, et al. Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis. 1998; 26:611-619.
120.
Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 1996; 335:392-398.
121.
Nightingale SD, Cameron W, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. 1993; 329:828-833.
122.
El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. N Engl J Med. 2000; 342:1085-1092.
123.
Furrer H, Telenti A, Rossi, et al. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS. 2000; 14:1409-1412.
124.
Freeman WR, Lerner CW, Mines JA, et al. A prospective study of the ophthalmologic findings in the acquired immunodeficiency syndrome. Am J Ophthalmol. 1984; 97:133-142.
125.
Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997; 349:1443-1445.
126.
Deayton JR, Wilson P, Sabin CA, et al. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS. 2000; 14:1163-1170.
127.
Drew WL. Cytomegalovirus infection in patients with AIDS. J Infect Dis. 1988; 158:449-456.
128.
Studies of Ocular Complicatons of AIDS Research Group, in Collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992; 326:213-220.
129.
Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989; 107:75-80.
130.
Palestine AG, Polis MA, DeSmet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991; 115:665-673.
131.
Jacobson MA, O’Donnell JJ, Mills J.Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency virus. Antimicrol Agents Chemother. 1989; 33:736-741.
132.
The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS. 1995; 9:471-477.
133.
Gross JB, Bozzette SA, Mathews WC, et al. Longitudinal study of cytomegalovirus retinitis in acquired immunodeficiency syndrome. Ophthalmology. 1990; 97:681-686.
134.
Orellana J, Teich SA, Friedman AH, et al. Combined short- and long-term therapy for treatment of cytomegalovirus retinitis using ganciclovir (BW B759U). Ophthalmology. 1987; 94:831-838.
135.
Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med. 1995; 333:615-620.
136.
Jacobson MA. Review of the toxicities of foscarnet. J Acquir Immue Deficiency Syndromes. 1992; 5(Suppl. 1):S11-S17.
137.
Kupperman BD, Flores-Aguilar M, Quiceno JI, et al. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Arch Ophthalmol. 1993; 111:1359-1366.
138.
The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol. 1996; 114:23-33.
139.
Anderson RD, Griffy KG, Jung D, et al. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000 mg/d dosing regimens in human immunodeficiency virus and cytomegalovirus-seropositive patients. Clin Ther. 1995; 17:425-432.
140.
Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis. 1995; 171:1431-1437.
141.
Jacobson MA, de Miranda P, Cederberg DM, et al. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother. 1987; 31:1251-1254.
142.
Plotkin SA, Drew WL, Felsenstein D, et al. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis. 1985; 152:833-834.
143.
Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol. 1994; 112:1531-1539.
144.
Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med. 1997; 337:83-90.
145.
Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med. 1999; 340:1063-1070.
146.
Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1997; 126:257-263.
147.
Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann Intern Med. 1997; 126:264-274.
148.
Berenguer J, Mallolas J, the Spanish Cidofovir Study Group. Intravenous cidofovir for compassionate use in AIDS patients with cytomegalovirus retinitis. Clin Infect Dis. 2000; 30:182-184.
149.
Manishchewitz JF, Quinnan GV, Lane HC, et al. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1990; 34:373-375.
150.
Brown F, Banken L, Saywell K, et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999; 37:167-176.
151.
Martin D, Sierra-Madero J, Walmsley S, et al. Valganciclovir (VGCV) vs. IV ganciclovir (GCV) as induction therapy for newly diagnosed cytomegalovirus (CMV) retinitis: a randomized, controlled study. In: Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 231.
152.
Feinberg J, Cooper D, Hurwitz S.Phase III international study of valacyclovir (VACV) for cytomegalovirus (CMV) prophylaxis in patients with advanced HIV disease. In: Abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia, Canada. Abstract no. Th.B.300.
153.
Macdonald JC, Karavellas MP, Torriani FJ, et al. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology. 2000; 107:877-903.
154.
Tural C, Romeu J, Sirera G, et al. Longlasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis. 1998; 177:1080-1083.
155.
Whicup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. 1999; 282:1633-1637.
156.
Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T Cells in response to highly active antiretroviral therapy. J Infect Dis. 1998; 177:1182-1187.
